These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35571990)

  • 1. Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
    Kohlmeyer JL; Kaemmer CA; Lingo JJ; Voigt E; Leidinger MR; McGivney GR; Scherer A; Koppenhafer SL; Gordon DJ; Breheny P; Meyerholz DK; Tanas MR; Dodd RD; Quelle DE
    Neurooncol Adv; 2022; 4(1):vdac047. PubMed ID: 35571990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development.
    Vélez-Reyes GL; Koes N; Ryu JH; Kaufmann G; Berner M; Weg MT; Wolf NK; Rathe SK; Ratner N; Moriarity BS; Largaespada DA
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapies for MPNSTs targeting RABL6A-RB1 signaling.
    Kohlmeyer JL; Gordon DJ; Tanas MR; Dodd RD; Monga V; Darbro BW; Quelle DE
    Oncotarget; 2021 Jan; 12(1):10-14. PubMed ID: 33456709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.
    Kohlmeyer JL; Kaemmer CA; Umesalma S; Gourronc FA; Klingelhutz AJ; Quelle DE
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors.
    Ki DH; He S; Rodig S; Look AT
    Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
    Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions.
    Zhou H; Coffin CM; Perkins SL; Tripp SR; Liew M; Viskochil DH
    Am J Surg Pathol; 2003 Oct; 27(10):1337-45. PubMed ID: 14508395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.
    Hirbe AC; Dahiya S; Friedmann-Morvinski D; Verma IM; Clapp DW; Gutmann DH
    Oncotarget; 2016 Feb; 7(7):7403-14. PubMed ID: 26859681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
    Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
    Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Oppel F; Ki DH; Zimmerman MW; Ross KN; Tao T; Shi H; He S; Aster JC; Look AT
    Dis Model Mech; 2020 Aug; 13(8):. PubMed ID: 32651197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
    Patrizi S; Miele E; Falcone L; Vallese S; Rossi S; Barresi S; Giovannoni I; Pedace L; Nardini C; Masier I; Abballe L; Cacchione A; Russo I; Di Giannatale A; Di Ruscio V; Salgado CM; Mastronuzzi A; Ciolfi A; Tartaglia M; Milano GM; Locatelli F; Alaggio R
    Clin Epigenetics; 2024 Jan; 16(1):9. PubMed ID: 38178234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo.
    Maharjan CK; Umesalma S; Kaemmer CA; Muniz VP; Bauchle C; Mott SL; Zamba KD; Breheny P; Leidinger MR; Darbro BW; Stephens SB; Meyerholz DK; Quelle DE
    Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.
    Lu HC; Eulo V; Apicelli AJ; Pekmezci M; Tao Y; Luo J; Hirbe AC; Dahiya S
    Oncotarget; 2018 May; 9(33):23018-23028. PubMed ID: 29796169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.